Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03423407
Other study ID # 201710134
Secondary ID 1R01CA212148-01
Status Terminated
Phase
First received
Last updated
Start date December 14, 2017
Est. completion date March 2, 2020

Study information

Verified date May 2022
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this research proposal is to establish a mechanism to develop tools that will allow the investigators to measure the impact of magnetic resonance (MR) acquisition correction sequences for attenuation correction on positron emission tomography (PET) quantitation accuracy.


Recruitment information / eligibility

Status Terminated
Enrollment 30
Est. completion date March 2, 2020
Est. primary completion date March 2, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant must be = 18 years of age - Participant can be a male or a non-pregnant female. - Successful completion of MRI screening form - Participant must have undergone a PET/CT examination with injection of a standard dose of 18F-fluorodeoxyglucose (FDG) or other PET tracer with a half-life greater than one hour either for clinical or research purposes within 3 hrs of the proposed PET-MRI examination. - Participant will be fully informed and has personally signed and dated the written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) provisions Exclusion Criteria: - Subjects for whom exposure to a strong magnetic field would be a health risk (e.g., subjects with cardiac pacemakers or non-MR compatible metallic implants) - Women who are pregnant. - Subjects who require sedation to participate will be excluded. - Patient/participant has a medical condition which in the judgment of the investigator might make supine positioning for the duration of the scan unsafe, such as (but not limited to) congestive heart failure or significant pulmonary disease.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
FDA approved scanner

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure the impact of MR acquisition correction sequences for attenuation correction on PET quantitation accuracy -PET images from PET/MRI with the MR derived attenuation correction will be compared to images generated with the CT attenuation correction from the standard of care PET/CT scan. At the time of the MRI scan
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05030597 - Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma N/A
Recruiting NCT05496920 - Assessing Ultra-low Dose PET/CT and CT-less PET Using a Long Axial Field-of-view PET/CT System N/A
Recruiting NCT04577586 - Negative Oral Contrast Agents Utilization in PET/CT Studies
Recruiting NCT04586465 - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC Phase 2
Recruiting NCT04553601 - Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer N/A
Recruiting NCT05707078 - PET/CT Follow up for Head and Neck Squamous Cell Carcinoma N/A
Recruiting NCT06320223 - PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
Recruiting NCT05255926 - CXCR4-targeted PET/CT Imaging in Hematological Malignancies N/A
Recruiting NCT05955677 - Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis Early Phase 1
Recruiting NCT04588064 - 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma N/A
Active, not recruiting NCT04519255 - Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT
Recruiting NCT05835570 - Integrin αvβ6-targeted PET in Malignant Tumors
Active, not recruiting NCT05819905 - Radiomics for prEdiction of lunG cAncer biologY
Recruiting NCT05034146 - 68Ga-FAPI PET/CT in Malignant Tumors N/A
Recruiting NCT05156515 - PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor N/A
Completed NCT05134064 - 68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer
Recruiting NCT03756077 - A Study of the Value of Hybrid PET/MR and PET/CT in Prostate Cancer
Recruiting NCT06462508 - Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis Early Phase 1
Not yet recruiting NCT06353061 - Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer Phase 2
Recruiting NCT06462495 - Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis Early Phase 1